Update Breast Cancer 2020 Part 3 – Early Breast Cancer

Author:

Huober Jens1,Schneeweiss Andreas2,Hartkopf Andreas D.3,Müller Volkmar4,Lux Michael P.5,Janni Wolfgang1,Ettl Johannes6,Belleville Erik7,Thill Marc8,Fasching Peter A.9,Kolberg Hans-Christian10,Schulmeyer Carla E.9,Welslau Manfred11,Overkamp Friedrich12,Tesch Hans13,Fehm Tanja N.14,Lüftner Diana15,Schütz Florian16,Wöckel Achim17

Affiliation:

1. Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany

2. National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany

3. Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany

4. Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany

5. Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Germany

6. Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

7. ClinSol GmbH & Co KG, Würzburg, Germany

8. Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt, Germany

9. Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany

10. Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany

11. Onkologie Aschaffenburg, Aschaffenburg, Germany

12. OncoConsult Overkamp, Berlin, Germany

13. Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany

14. Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany

15. Charité University Hospital, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany

16. Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany

17. Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany

Abstract

AbstractThe treatment of patients with early breast cancer has always been characterised by escalation by new therapies and de-escalation through identification of better treatment regimens or introduction of better tools to estimate prognosis. Efforts in some of these areas in the last few years have led to solid data. The results of the large studies of de-escalation through use of multi-gene tests are available, as are the results of some studies that investigated the new anti-HER2 substances T-DM1 and pertuzumab in the early treatment situation. Several large-scale studies examining the role of CDK4/6 inhibitors will soon be concluded so innovations can be anticipated in this area also. This review article will summarise and classify the results of the latest publications.

Publisher

Georg Thieme Verlag KG

Subject

Maternity and Midwifery,Obstetrics and Gynaecology

Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3